Theranexus Société Anonyme (ALTHX.PA)
EUR 0.39
(0.69%)
EUR 0.39
(0.69%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -4.63 Million EUR | -5695.66% |
| 2022 | 82.89 Thousand EUR | 100.94% |
| 2021 | -8.82 Million EUR | -66.03% |
| 2020 | -5.31 Million EUR | 21.22% |
| 2019 | -6.74 Million EUR | -2.69% |
| 2018 | -6.56 Million EUR | -394.12% |
| 2017 | -1.32 Million EUR | 1.42% |
| 2016 | -1.34 Million EUR | -141.61% |
| 2015 | -558.09 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 964.25 Thousand EUR | 0.0% |
| 2023 Q4 | -2.59 Million EUR | 0.0% |
| 2023 FY | 40.06 Thousand EUR | -51.67% |
| 2023 Q2 | 75.91 Thousand EUR | 0.0% |
| 2022 Q4 | -164.26 Thousand EUR | 0.0% |
| 2022 FY | 82.89 Thousand EUR | 100.94% |
| 2022 Q2 | 246.95 Thousand EUR | 0.0% |
| 2021 Q2 | -2.86 Million EUR | 0.0% |
| 2021 FY | -8.82 Million EUR | -66.03% |
| 2021 Q4 | -2.6 Million EUR | 0.0% |
| 2020 Q4 | -2.33 Million EUR | 0.0% |
| 2020 FY | -5.31 Million EUR | 21.22% |
| 2020 Q2 | -2.97 Million EUR | 0.0% |
| 2019 FY | -6.74 Million EUR | -2.69% |
| 2019 Q4 | -3.41 Million EUR | 0.0% |
| 2019 Q2 | -3.33 Million EUR | 0.0% |
| 2018 FY | -6.56 Million EUR | -394.12% |
| 2018 Q4 | -3.82 Million EUR | 0.0% |
| 2018 Q2 | -2.74 Million EUR | 0.0% |
| 2017 FY | -1.32 Million EUR | 1.42% |
| 2017 Q4 | -834.49 Thousand EUR | 0.0% |
| 2017 Q1 | -332.32 Thousand EUR | 55.49% |
| 2017 Q2 | -479.93 Thousand EUR | -44.42% |
| 2016 Q2 | -574.08 Thousand EUR | -59.58% |
| 2016 FY | -1.34 Million EUR | -141.61% |
| 2016 Q1 | -359.74 Thousand EUR | -0.0% |
| 2016 Q4 | -746.55 Thousand EUR | 0.0% |
| 2015 Q2 | -279.86 Thousand EUR | 0.0% |
| 2015 Q3 | -279.86 Thousand EUR | -0.0% |
| 2015 Q4 | -359.74 Thousand EUR | -28.54% |
| 2015 FY | -558.09 Thousand EUR | 0.0% |
| 2015 Q1 | -279.86 Thousand EUR | -0.0% |
| 2014 Q4 | -279.86 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 850.597% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 218.515% |
| Adocia SA | 1.38 Million EUR | 434.923% |
| Aelis Farma SA | 12.35 Million EUR | 137.536% |
| Biophytis S.A. | -803 Thousand EUR | -477.67% |
| Advicenne S.A. | 1.42 Million EUR | 425.294% |
| genOway Société anonyme | 20.1 Million EUR | 123.078% |
| IntegraGen SA | 5.01 Million EUR | 192.436% |
| Medesis Pharma S.A. | -2.66 Million EUR | -74.075% |
| Neovacs S.A. | 29.31 Thousand EUR | 15924.145% |
| NFL Biosciences SA | -56.06 Thousand EUR | -8173.919% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 315.461% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | -226.832% |
| Sensorion SA | 3.78 Million EUR | 222.462% |
| TME Pharma N.V. | -127 Thousand EUR | -3552.512% |
| Valbiotis SA | 2.66 Million EUR | 273.864% |
| TheraVet SA | -530.79 Thousand EUR | -773.912% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 466.116% |
| DBV Technologies S.A. | 4.15 Million EUR | 211.518% |
| Genfit S.A. | 28.22 Million EUR | 116.435% |
| GeNeuro SA | -293.8 Thousand EUR | -1478.86% |
| Innate Pharma S.A. | -4.12 Million EUR | -12.562% |
| Inventiva S.A. | 17.5 Million EUR | 126.507% |
| MaaT Pharma SA | 1.65 Million EUR | 380.283% |
| MedinCell S.A. | 9.28 Million EUR | 149.943% |
| Nanobiotix S.A. | 36.2 Million EUR | 112.811% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 308.293% |
| Poxel S.A. | 1000.00 EUR | 463969.0% |
| GenSight Biologics S.A. | 3 Million EUR | 254.623% |
| Transgene SA | -28.4 Million EUR | 83.669% |
| Valneva SE | 52.83 Million EUR | 108.779% |